Telmisartan is an angiotensin II receptor antagonist. Telmisartan keeps blood vessels from narrowing, which lowers blood pressure and improves blood flow. Telmisartan is used to treat high blood pressure (hypertension). It is sometimes given together with other blood pressure medications. Telmisartan is also used to reduce the risk of stroke, heart attack, or death from heart problems in people who are at least 55 years old with risk factors for serious heart disorders.
The Telmisartan market revenue was xx.xx Million USD in 2019, and will reach xx.xx Million USD in 2025, with a CAGR of x.x% during 2020-2025.

Under COVID-19 outbreak globally, this report provides 360 degrees of analysis from supply chain, import and export control to regional government policy and future influence on the industry. Detailed analysis about market status (2015-2020), enterprise competition pattern, advantages and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to end users of this industry are analyzed scientifically, the trends of product circulation and sales channel will be presented as well. Considering COVID-19, this report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

In COVID-19 outbreak, Chapter 2.2 of this report provides an analysis of the impact of COVID-19 on the global economy and the Telmisartan industry.
Chapter 3.7 covers the analysis of the impact of COVID-19 from the perspective of the industry chain.
In addition, chapters 7-11 consider the impact of COVID-19 on the regional economy.

The Telmisartan market can be split based on product types, major applications, and important countries as follows:

Key players in the global Telmisartan market covered in Chapter 12:
Takeda
Ratiopharm
Hidaa Lifescience
Dawnrays Pharmaceutical Limited
China Resources Double Crane Pharmaceutical
Hainan Selection Pharmaceutical
Novartis
Yichang Changjiang Pharmaceutical
Astellas Pharma Inc
Beijing Wansheng Pharmaceutical
Wanbang Biopharmaceuticals
Nippon Boehringer Ingelheim Co
Reddy'S Laboratories (Uk) Limited
Abbott
Hema Pharmaceuticals Pvt
Teva
Bayer
Pfizer
Boehringer Ingelheim
Mylan
Gsk

In Chapter 4 and 14.1, on the basis of types, the Telmisartan market from 2015 to 2025 is primarily split into:
Injection
Freeze-Dried Powder

In Chapter 5 and 14.2, on the basis of applications, the Telmisartan market from 2015 to 2025 covers:
Hospital Use
Clinic
Others

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2025) of the following regions are covered in Chapter 6, 7, 8, 9, 10, 11, 14:
North America (Covered in Chapter 7 and 14)
United States
Canada
Mexico
Europe (Covered in Chapter 8 and 14)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 9 and 14)
China
Japan
South Korea
Australia
India
Southeast Asia
Others
Middle East and Africa (Covered in Chapter 10 and 14)
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
Others
South America (Covered in Chapter 11 and 14)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:
Historical Years: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Period: 2020-2025